Switzerland-headquartered Alcon plans to build a facility in Singapore that will manufacture pharmaceuticals to be distributed throughout most of Asia. The company aims to break ground in 2009 with the plant being fully functional in 2012. The new Alcon unit is expected to employ more than 150 people within three years after commencing production.
Ophthalmics specialist Alcon, which is majority owned by Swiss food giant Nestle, is currently the subject of a two-part takeover agreement from pharmaceuticals major Novartis (Marketletter April 14).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze